90
Views
4
CrossRef citations to date
0
Altmetric
Original Research

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts

, , &
Pages 53-67 | Published online: 22 Mar 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Taylor P Berke, Simon H Slight & Salman M Hyder. (2022) Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer. OncoTargets and Therapy 15, pages 23-30.
Read now
Yayun Liang, Cynthia Besch-Williford, Matthew T Cook, Anthony Belenchia, Rolf A Brekken & Salman M Hyder. (2019) APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. Breast Cancer: Targets and Therapy 11, pages 249-259.
Read now

Articles from other publishers (2)

Ashwini Makhale, Devathri Nanayakkara, Prahlad Raninga, Kum Kum Khanna & Murugan Kalimutho. (2021) CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer. International Journal of Molecular Sciences 22:11, pages 5782.
Crossref
Elizabeth A. Lopes, Sara Gomes, Lucília Saraiva & Maria M.M. Santos. (2020) Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. Current Medicinal Chemistry 26:41, pages 7323-7336.
Crossref